pragma.vision Your technology observatory

Verification register Bio, Health & Neuro

Readiness verdict

NewLimit Liver Reprogramming Medicine (LNP-RNA transcription factors)

A dated reading of what is claimed, reported, and independently verified in the current evidence.

As of
2026-06-28
Revision
1
Method
v1.0.0

Current reading

The readiness gap, in one scan

AI-assisted assembly · derived results

Claimed
30

Public ambition and stated capability

Reported
30

Observed practitioner reporting

Verified
28

Independently supported evidence

Gap
+2

Claimed minus verified

Evidence strength Strong

Decision

What the current evidence supports

Human editorial judgment · 2026-06-28

Wait for stronger evidence

Why
A $435M raise and a credible LNP-RNA platform make this a serious player, but it is preclinical with clinic entry still ~a year out and no published human-relevant efficacy numbers — strong momentum, weak evidence
Next
Monitor for the IND filing and the planned ~2027 first-in-human liver trial; require peer-reviewed quantified preclinical efficacy (not payload-engineering deltas) before upgrading from watch status

Constraints

Blockers

No named blocker is present in the current public projection.

Evidence summary

Derived counts

AI-assisted assembly

Total
6
Tier 1
0
Tier 2
2
Tier 3
4
Supports
2
Contradicts
1
Context
3
Latest observed
2026-06-01

Counts and dates only. Raw signals, private excerpts, trust records, and internal corpus material are not published here.

Publication record

Revisions

Initial public reading

This is the initial public reading. No earlier readiness change is recorded.

Your opinion

Tell us anything.

What works, what doesn't, what's missing — especially about our watches, lenses, and the register itself. Anonymous is fine; leave an email if you'd like a reply.